Inclusion Criteria:~1. A man or a woman between the ages of 55 and 85 years (inclusive)~2. Meets National
Institute on Aging-Alzheimer's Association (NIA-AA) clinical diagnostic criteria for AD dementia~3. Has
evidence of AD pathological process by a positive amyloid assessment with cerebrospinal fluid (CSF) AÎ²42~4.
Has a Clinical Dementia Rating (CDR) global score of 0.5 or 1~5. Has a Mini-Mental State Exam (MMSE) Score of
18 to 26 (inclusive)~6. Has a 15-item Geriatric Depression Scale (GDS) score of < 6~7. Impaired memory
performance below education adjusted cut-off score on the Logical Memory II subscale delayed paragraph recall
(LM-IIa) of the Wechsler Memory Scale-Revised (WMS-R) (≥16 years: ≤8; 8-15 years: ≤4; 0-7 years: ≤2)~8. May
take Food and Drug Administration (FDA) approved medications for the treatment of AD dementia (cholinesterase
inhibitors and/or memantine), but if taking such medications, they must be stable for at least 8 weeks before
screening~9. Has adequate visual and auditory acuity to participate in neuropsychological testing and other
study assessments~10. Has the availability of an informant (study partner) who has regular contact with the
participant and knows him/her well~11. Is willing and able to participate in all assessments in English~12. Is
capable of providing written informed consent~
